An experimental drug—MDV3100—that has
been in trials for several years has shown very positive results. There has been a
significant survival benefit demonstrated in phase III studies. Nearly 1200 men who had
undergone late stage chemotherapy participated in the double blind study—nobody
knew who was getting the experimental drug and who was getting the placebo
(neutral substance).
The principal investigator said that the MDV3100 study ‘exceeded our expectations’.
Men taking the experimental drug lived significantly longer, had lower PSA
scores, and the side effects were ‘well tolerated’ or what we’d call not so
bad. Just about all cancer medications have side effects so a successful drug
with moderate side effects is considered good. The trial was so successful it
was stopped early and those men who were receiving the placebo were offered the
MDV3100.
It has to be approved by the FDA before it can be prescribed
by doctors. Many drugs never make it through the clinical trials process so
this is seen as very important.
If you have prostate cancer, watch for further news. By the
time it is approved it will likely have a new (and better) name.
axman
1 comment:
This blog is great source of information which is very useful for me. Thank you very much.
BEST INFORMATION ABOUT PROSTATE CANCER.
Post a Comment